Carleo R, Gobbo M, Bonavita M, De Matteo A, Gallo M, Gatti A
Mal del Ricambio e Nutrizione Clinica, Ospedale San Gennáro, Napoli.
Boll Soc Ital Biol Sper. 1990 Jul;66(7):639-46.
In this report the Authors have verified the effects of Ketanserin on glycaemic metabolism of type II diabetic subjects with a moderately high blood pressure. They think that a therapeutic dose of drug is not able to considerably inhibit insulin production. The Authors can assert that the Ketanserin does not influence the glycaemic regulation by therapeutic dose, neither does it increase the diabetic disease, nor disturb the oral hypoglycaemic therapy though it normalizes high blood pressure.
在本报告中，作者验证了酮色林对中度高血压的II型糖尿病患者血糖代谢的影响。他们认为，治疗剂量的该药物无法显著抑制胰岛素分泌。作者可以断言，酮色林在治疗剂量下不会影响血糖调节，既不会加重糖尿病病情，也不会干扰口服降糖治疗，尽管它能使高血压恢复正常。
